MedPath

effects of Olive Oil in non-alcoholic fatty liver disease patients

Not Applicable
Conditions
non-alcoholic fatty liver.
Fatty ( change of ) liver , not elsewhere classified
Registration Number
IRCT201111022709N20
Lead Sponsor
Vice-chancellor for Research, Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Inclusion Criteria: signing written informed consent, age between 20and 60, diagnosis of non-alcoholic fatty liver disease by fatty infiltration on ultrasound and abnormal serum liver function tests (AST or ALT>30 u/l in men and >20 in women), no smoking, BMI between 25 to 35, no pregnancy or lactation, no use of dietary supplements 2 month prior to enrollment, not having diabetes, , acute heart disease, , other form of liver disease (viral or autoimmune hepatitis, metabolic and hereditary liver disease), no usual use of Olive Oil in dietary pattern, no use of drugs that induces steatosis (amidarone, methotrexate, systemic glucocorticoid, tetracycline, tamoxifen, estrogen, anabolic steroids, valporic acid) , no use of Lipid lowering drugs .

Exclusion Criteria

those who are not interested in participating in the study, start using drugs affecting liver functiont, failure to complete or correct use of Olive Oil according to the instruction given , change in recommended diet and daily physical activity

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum ALT. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: IFCC,IU/D.;Sserum AST. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: IFCC,IU/D.;Steatosis severity. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: Sonography.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath